Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomics-clinical diagnostic tests for cancer. The Company uses its technologies that enable the Company to extract ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE) specimens and to analyze genetic information contained in these tissues for each patient. The Company�s platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company primarily sells ResponseDX diagnostic testing products and provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.